Davangere P. Devanand, MBBS
Professor of Psychiatry (in Neurology and in the Gertrude H. Sergievsky Center) at CUMC
Dr. D. P. Devanand is Professor of Clinical Psychiatry and Neurology at the College of Physicians and Surgeons, Columbia University. He completed medical school at Christian Medical College, Vellore, in India, and trained in psychiatry at the National Institute of Mental Health and Neurosciences, Bangalore, India.
He completed psychiatry residency training at S.U.N.Y. Upstate Medical Center, Syracuse, and Yale University School of Medicine. He then did a clinical research fellowship in Biological Psychiatry at Columbia University, and has continued on the faculty at Columbia University since 1987. Currently, he is Co-Director of the Memory Disorders Center, and Co-Director of the Late Life Depression Clinic, at the New York State Psychiatric Institute. His research studies involve Alzheimer’s disease, geriatric depression and electroconvulsive therapy. His research has helped define the clinical features and treatment response in elderly patients with chronic mild to moderate depression, or dysthymic disorder.
He pioneered studies on the interface between depression and cognitive impairment in the elderly, and he is also known for his research into early diagnostic markers of Alzheimer’s disease and the treatment of behavioral complications in Alzheimer’s disease. He has been principal investigator on several research grants from the National Institute of Aging and the National Institute of Mental Health. He has also been funded by the Alzheimer’s Association, NARSAD, and the Dana Foundation.
He has published over 180 research papers and articles, and is the author of three books.
Herbert Pardes Building of the New York State Psychiatric Institute
1051 Riverside Drive
Unit 126 New York, NY 10032
Phone: (212) 543-5612
Fax: (212) 543-5088
Public Transportation: Yes
Disabled Access: Yes
Research interests include treatment strategies for mild cognitive impairment and Alzheimer's disease, including treatment of psychosis and agitation in these disorders. Other interests include early diagnostic markers of Alzheimer's disease, and the interface between depression and cognitive impairment.
1) Study of olfactory identification deficits in the prediction of response to treatment with FDA-approved cholinesterase inhibitors in patients with mild cognitive impairment and mild to moderate Alzheimer's disease.
2) Study of low dose lithium to treat patients with Alzheimer's disease who develop symptoms of agitation, aggression, delusions or hallucinations.
Both studies are funded by the National Institute of Aging, a branch of the National Institutes of health.